

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

SECRETARY OF THE SENATE
03 AUG 21 PM 3:17

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name AstraZeneca Pharmaceuticals LP			
2. Address <input type="checkbox"/> Check if different than previously reported 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437			
3. Principal Place of Business (if different from line 2) City: _____ State/zip (or Country) _____			
4. Contact Name Michele C. Campbell		Telephone (302) 886-1101	E-mail (optional) _____
5. Senate ID # _____			6. House ID # 34975000
7. Client Name <input checked="" type="checkbox"/> Self			

TYPE OF REPORT 8. Year 2003 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇨ Termination Date _____

11. No Lobbying

INCOME OR EXPENSES Complete Either Line 12 OR Line 13	
<p align="center">12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ _____ Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center">13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇨ \$ <u>680,000.00</u> Expenses (nearest \$20,000)</p>
<p>14. REPORTING METHOD. Check box to indicate expected accounting method. See instructions for description of options.</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definition</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(c) Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) Internal Revenue Code</p>	

Signature Michele C. Campbell Date 08/13/03

Printed Name and Title Michele C. Campbell, Senior Counsel

LD-2 (REV. 4/03)

PAGE 1 of

Registrant Name AstraZeneca Pharmaceuticals LP Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which th engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each co information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

H.R. 1 - Medicare Prescription Drug and Modernization Act of 2003
S. 1 - Prescription Drug and Medicare Improvement Act of 2003

Calls, letters and visits in support of a private sector, premium support approach to a Medicare drug benefit.

17. House(s) of Congress and Federal agencies contacted Check if None

U.S. House of Representatives
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
James P. Schlicht	Vice President, Government Affairs
Stephen D. McMillan	Senior Manager, Federal Governmant Affairs
Jacqueline Pomfret	Senior Manager, Federal Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature *Michelle C. Camp* Date 08/13/03

Printed Name and Title Michele C. Campbell, Senior Counsel

Form LD-2 (Rec. 4/03)

Page 2

Registrant Name AstraZeneca Pharmaceuticals LP Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code and information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

H.R. 1288/S.1037 - Access to Cancer Therapies Act of 2003.
Calls and visits in support of passage and enactment.

17. House(s) of Congress and Federal agencies contacted Check if None

U.S. House of Representatives
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
James P. Schlicht	Vice President, Government Affairs
Stephen D. McMillan	Senior Manager, Federal Government Affairs
Jacqueline Pomfret	Senior Manager, Federal Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature *Michael C. ...* Date 08/13/03

Printed Name and Title Michele C. Campbell, Senior Counsel

Form LD-2 (Rec. 4/03)

Page 3

Registrant Name AstraZeneca Pharmaceuticals LP Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each co information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific lobbying issues

H.R. 2673/S. 1427 - Agriculture, FDA and Related Agencies Appropriations, FY 2004.
Calls and visits to members to oppose Northrop Amendment on reimportation.

17. House(s) of Congress and Federal agencies contacted Check if None

U.S. House of Representatives
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
James P. Schlicht	Vice President, Government Affairs
Stephen D. McMillan	Senior Manager, Federal Government Affairs
Jacqueline Pomfret	Senior Manager, Federal Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 08/13/03

Printed Name and Title ^v Michele C. Campbell, Senior Counsel

Form LD-2 (Rev. 4/03)

Page 4

Registrant Name AstraZeneca Pharmaceuticals LP Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code and information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific lobbying issues

S. 1225 - Greater Access to Affordable Pharmaceuticals Act of 2003.
 Calls and visits in opposition.


17. House(s) of Congress and Federal agencies contacted Check if None

U.S. House of Representatives
 U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<u>James P. Schlicht</u>	Vice President, Government Affairs
<u>Stephen D. McMillan</u>	Senior Manager, Federal Government Affairs
<u>Jacqueline Pomfret</u>	Senior Manager, Federal Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 08/13/03

Printed Name and Title

Michele C. Campbell, Senior Counsel

Form LD-2 (Rec. 4/03)

Page 5

Registrant Name AstraZeneca Pharmaceuticals LP Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code and information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific lobbying issues

S. 650 - Pediatric Research Equity Act.
 Calls and visits to support extension of pediatric provisions of the Federal Food, Drug, and Cosmetic Act.

17. House(s) of Congress and Federal agencies contacted Check if None

U.S. House of Representatives
 U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
James P. Schlicht	Vice President, Government Affairs
Stephen D. McMillan	Senior Manager, Federal Government Affairs
Dyan McGrath	Senior Manager, Federal Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 08/13/03

Registrant Name AstraZeneca Pharmaceuticals LP Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which th engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each co information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

H.R. 2427 - Pharmaceutical Market Access Act of 2003.
Calls, letters and visits relatec to proposed changes to the Federal Food, Drug and Cosmetic Act.


17. House(s) of Congress and Federal agencies contacted Check if None

U.S. House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
James P. Schlicht	Vice President, Government Affairs
Stephen D. McMillan	Senior Manager, Federal Governmant Affairs
Jacqueline Pomfret	Senior Manager, Federal Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 08/13/03

✓ ✓
Printed Name and Title

Michele C. Campbell, Senior Counsel

Form LD-2 (Rec. 4/03)

Page 7